Enhanced safety and efficacy of protease-regulated CAR-T cell receptors
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA794116 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR17425773_1.fastq.gz | Fastqsanger.gz | |||
| SRR17425773_2.fastq.gz | Fastqsanger.gz | |||
| SRR17425774_1.fastq.gz | Fastqsanger.gz | |||
| SRR17425774_2.fastq.gz | Fastqsanger.gz | |||
| SRR17425775_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 22 |
Similar Datasets
Project description:Regulatable CAR platforms could circumvent toxicities associated with CAR-T therapy, but existing systems have shortcomings including leakiness and attenuated activity. Here, we present SNIP-CARs, a novel protease-based platform for regulating CAR activity using an FDA-approved small molecule. Design iterations yielded CAR-T cells that manifest full functional capacity with drug and no leaky activity in the absence of drug. In numerous models, SNIP CAR-T cells were more potent than constitutive CAR-T cells and showed diminished T cell exhaustion and greater stemness. In a ROR1-based CAR lethality model, drug cessation following toxicity onset reversed toxicity, thereby credentialling the platform as a safety switch. In the same model, reduced drug dosing opened a therapeutic window that resulted in tumor eradication in the absence of toxicity. SNIP-CARs enable remote tuning of CAR activity, which provides solutions to safety and efficacy barriers currently limiting progress in using CAR T cells to treat solid tumors.
2022-03-09 | GSE192998 | GEO
Project description:Regulatable CAR platforms could circumvent toxicities associated with CAR-T therapy, but existing systems have shortcomings including leakiness and attenuated activity. Here, we present SNIP CARs, a protease-based platform for regulating CAR activity using an FDA-approved small molecule. Design iterations yielded CAR-T cells that manifest full functional capacity with drug and no leaky activity in the absence of drug. In numerous models, SNIP CAR-T cells were more potent than constitutive CAR-T cells and showed diminished T cell exhaustion and greater stemness. In a ROR1-based CAR lethality model, drug cessation following toxicity onset reversed toxicity, thereby credentialing the platform as a safety switch. In the same model, reduced drug dosing opened a therapeutic window that resulted in tumor eradication in the absence of toxicity. SNIP CARs enable remote tuning of CAR activity, which provides solutions to safety and efficacy barriers that are currently limiting progress in using CAR-T cells to treat solid tumors.
| S-EPMC9467936 | biostudies-literature
Project description:The efficacy of chimeric antigen receptor (CAR) T cell therapy in solid tumors is limited by immunosuppression and antigen heterogeneity. To overcome these barriers, “armored” CAR T cells, which secrete proinflammatory cytokines, have been developed. However, their clinical application has been limited due to toxicities related to peripheral expression of the armoring transgene. Here, we developed a CRISPR knock-in strategy that leverages the regulatory mechanisms of endogenous genes to drive transgene expression in a tumor-localized manner. By screening endogenous genes with tumor-restricted expression, the NR4A2 and RGS16 promoters were identified to support the delivery of cytokines such as IL-12 and IL-2 directly to the tumor site, leading to enhanced anti-tumor efficacy and long-term survival of mice in both syngeneic and xenogeneic models. This was concomitant with improved CAR T cell polyfunctionality, activation of endogenous anti-tumor immunity, a favorable safety profile, and was applicable using CAR T cells from patients.
2025-06-18 | GSE292859 | GEO
Project description:CRISPR engineering of armored CAR T cells enables tumor-restricted payload delivery with enhanced safety and efficacy
| PRJNA1241771 | ENA
Project description:GPC2 and GD2 are validated CAR T cell targets in neuroblastoma, but durable responses remain limited. We profiled the surfaceome of neuroblastoma-derived extracellular vesicles (EVs) and assessed their impact on CAR T cell function. Neuroblastoma EVs displayed GPC2 and GD2, with minimal PD-L1, and were detected in blood from tumor-bearing mice and patients. These EVs directly activated paired CAR T cells, suggesting a role for a peripheral source of CAR antigen. To exploit this therapeutically, we engineered non-tumor-derived GPC2+ synthetic EVs (SyntEVs) as CAR T cell enhancers and armored them with either albumin- or GD2-binding domains. In mice harboring human neuroblastomas, serial infusion of armored SyntEVs following GPC2 CAR T cells enhanced tumor control by boosting peripheral CAR T cell persistence. Moreover, GD2-targeting SyntEVs decorated low-antigen tumor cells with GPC2, circumventing antigen downregulation. This SyntEV platform offers a versatile system to address the therapeutic limitations of CAR T cells in solid tumors.
2026-01-29 | PXD067632 | Pride
Project description:The widespread application of CAR T cell therapy to solid tumors is hindered by antigen expression heterogeneity, on-target off-tumor toxicity, and limited functional persistence of CAR T cells. Next generation engineering strategies aiming to overcome these hurdles rely on multiple antigen-targeting approaches that fail to simultaneously address all the limitations and/or the use of synthetic receptor transcriptional circuits, which suffer from slow activation kinetics. Here, we leveraged the unique trafficking properties of CTLA-4, regulated by a rapid internalization process, to create CTLA-4-based activation-inducible antigen receptors (CAVI-Rs). CAVI-Rs were exclusively expressed on T cells upon activation with remarkably fast on/off kinetics and self-sustainable expression. In in vitro and in vivo models of heterogeneous tumors, CAR+CAVI-R dual-engineered T cells demonstrated enhanced cytotoxicity and tumor-selective, spatially restricted functionality. Additionally, intermittent co-expression of the CAVI-R lead to improved T cell metabolic and transcriptional fitness, resulting in superior expansion, persistence and anti-tumor efficacy. The CAVI-R provides a novel, simple, safe, potent, and fully-human approach to expand CAR T cell applicability while improving anti-tumor outcomes.
2025-11-23 | GSE310581 | GEO
Project description:Neuroblastoma is a common pediatric extracranial solid tumor, that arises in the developing sympathetic nervous system. Chimeric antigen receptor (CAR) T-cell therapy has demonstrated promising clinical responses, yet its effectiveness in neuroblastoma benefits only a subset of patients. We evaluated the immunosuppressive secretome of neuroblastoma tumoroids that attenuate CAR T-cells function and efficacy. Secreted proteins were collected from tumoroids and identified by shotgun MS.
2025-04-02 | PXD051044 | Pride
Project description:The nuclear receptors CAR (constitutive androstane receptor) and PXR (pregnane X receptor) mediate the effects of phenobarbital (PB) on gene transcription. To investigate the relative role of CAR and PXR in the induction response, cDNA arrays were generated containing 120 genes which are known to be regulated with these or related nuclear receptors (genes involved in drug metabolism, cholesterol biosynthesis, sterol synthesis/transport, heme synthesis). Samples from livers of wild type and CAR-/-, PXR-/- or CAR/PXR-/- knockout mice were tested after treatment with PB for gene expression within the European Framework V program “Steroltalk” (www.steroltalk.net). Results from these experiments unexpectedly revealed that if CAR and PXR are deleted, PB increases the expression of several other nuclear receptors and genes involved in drug metabolism and cholesterol biosynthesis. Animals were injected i.p. 100mg/kg phenobarbital or vehicle (5% DMSO in corn oil). After 12h they were sacrificed and total RNA was isolated from the livers. Pools of untreated samples were mixed in each genetic variant group (wild type and CAR-/-, PXR-/- or CAR/PXR-/-) with the phenobarbital treated ones and hybridized to Sterolgene V1 arrays.
2008-08-23 | E-GEOD-12489 | biostudies-arrayexpress
Project description:Adoptive cell therapy with genetically engineered T cells expressing Chimeric Antigen Receptors (CARs) of high binding affinity has proven to be remarkably successful in refractory and relapsed B-cell malignancies. However, its broader clinical potential remains underexploited by the development of side effects due to intense CAR-T cell activation, as well as tumor relapse due to antigen-escape and limited persistence of CAR-T cells during sustained activation via high-affinity receptors. These challenges highlight the critical need for strategies that maximize the safety and efficacy of CAR-T cell therapies. Recent studies suggest that optimal adjustments of the CAR binding affinity to its ligand offers promising opportunities. In this study, we characterized a broad range of CARs with varying affinities for the same target epitope down to physiological TCR-like binding interactions. While CAR affinity had minimal impact on in vitro functionality across a broad range, it strongly correlated with tumor control in vivo, which was significantly compromised for low-affinity binders. On the other hand, CARs with lower affinity induced only mild cytokine release syndrome (CRS) in humanized mouse models. Based on these findings, we implemented an affinity-combination approach to leverage the strong anti-tumor efficacy of high-affinity CARs alongside the enhanced safety profile of lower-affinity CARs. We observed strong synergistic effects in combined products, like lower monocyte-induced cytokine production as compared to high-affinity CAR-T cells alone, while preserving efficacy. High-affinity CARs maintained strong functionality in mixtures with low-affinity CARs going along with strongly reduced signs of exhaustion when applied in combination. In long-term in vitro and in vivo settings, low-affinity CAR-T cells dominated over time proving more resilience to chronic antigen exposure, comparable to physiological T cell responses. Overall, our findings demonstrate that affinity-combination might be an attractive strategy to generate more effective CAR-T cell products with an improved therapeutic index.
2026-03-04 | GSE322706 | GEO
Project description:Chimeric Antigen Receptor T cells express an extracellular domain consisting of a single-chain fragment variable (scFv) targeting a surface tumor-associated antigen (TAA), it is important to select scFv regarding safety profile through evaluation of the efficacy/toxicity balance, especially in cases where the target antigen is also expressed on healthy cells. Here, we developed five CAR T cells targeting CD123 (CD123 CAR-T) by substituting only the scFv, looking for differences in terms of efficacy and on-target/off-tumor effects. Using in vitro models, we found that three of the five CD123 CAR-T were more cytotoxic against leukemic cells, without increasing lysis of monocytes or endothelial cells. Using the Incucyte system, we confirmed the low cytotoxicity of CD123 CAR-T on endothelial cells. Hematotoxicity evaluated by progenitor culture and CD34 cell lysis showed that two of the five CD123 CAR-T were less cytotoxic against HSC, and we confirmed in a humanized mouse model that CD123- cells were not eliminated by the CD123 CAR-T. These two CD123 CAR-T reduced tumor infiltration and increased overall survival of mice in three in vivo models of BPDCN. Moreover, in BPDCN aggressive model, bulk RNA-sequencing analysis showed that these CD123 CAR-T upregulated genes associated with cytotoxicity and activation/exhaustion a few days after the injection. Finally, we were able to produce CD123 CAR-T selected previously from patient T cells. Together, these results emphasize the importance of screening different scFv for the development of CAR-T constructs, to select the one with the optimal risk-benefit ratio for clinical development.
2024-06-03 | GSE253738 | GEO